m.Stock by Mirae AssetOpen Demat Account
m.Stock by Mirae Asset
Venmax Drugs & Pharmaceuticals Ltd logo

Venmax Drugs & Pharmaceuticals Ltd Share Price

Current price unavailable.
As on - | -
PharmaceuticalsSmall Cap

Volume Analysis

SPOT Pivot Levels

TypeClassicFibonacci
R1 --
R2--
R3--
PP- -
S1--
S2--
S3 --

Ratios

ParticularsDec 2025Sep 2025Jun 2025Mar 2025Dec 2024
ROCE-3.110.3-0.367.09
ROE-4.020.36-0.2451.69
EPS0.050.050.071.49-0.95

Peer Comparison

No data available
Scrip NamePriceDaily changeM CapPE Ratio1 Year Return

Corporate Action

April 14, 2026
<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=1px><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> </tr> <tr><td>1</td><td>Name of Company</td><td>Venmax Drugs and Pharmaceuticals Ltd</td></tr> <tr><td>2</td><td>CIN NO.</td><td>L24230TG1988PLC009102</td></tr> <tr><td>3</td> <td>Outstanding borrowing of company as on 31st March / 31st December as applicable (in Rs cr)</td> <td>0.00</td></tr> <tr><td>4</td><td>Highest Credit Rating during the previous FY </td><td>0</td></tr> <tr><td>4a</td><td>Name of the Credit Rating Agency issuing the Credit Rating mentioned in (4)</td><td>Not Applicable</td></tr> <tr><td>5</td><td>Name of Stock Exchange# in which the fine shall be paid in case of shortfall in the required borrowing under the framework</td><td>BSE</td></tr> </table> <br/><br/> <div> <div style=float:left;> We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018. No</div> <br/><br/><br/> <div style=float:left;> Name of the Company Secretary: Priyanka Agarwal <br/> Designation: Company Secretary and Compliance Officer <br/> EmailId: venmaxdrugs@gmail.com</div> <div style=float:left;margin-left:50px;> Name of the Chief Financial Officer: Kummarikuntla Saibaba <br/> Designation: Chief Financial Officer <br/> EmailId: venmaxdrugs@gmail.com</div> </div> <div> <br/> Date: 14/04/2026<br/><br/> <b>Note:<b> In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. </div>

About Venmax Drugs & Pharmaceuticals Ltd

Equity img
Venmax Drugs & Pharmaceuticals Limited, (VDPL) was initially incorporated as Private Company as 'Yenkay Medico Private Limited', on 28 September, 1998. The Company thereafter changed its name to 'Yenkey Drugs & Pharmaceuticals Private Limited' on 18 January, 1995. It became a Public Limited Company on February 3, 1995 as 'Yenkey Drugs & Pharmaceuticals Limited'. Finally, the Company changed its na...
ISIN :INE154G01022

Registered Office

Sy No 115 Brig Sayeed Road,Hanumanji Colony Old Bowenpall

Contact number

-

Registrars

CIL Securities Limited
214 RaghavaRatna Tow Chiragali Lane Abids Hyderabad 500001

Contact number

+ 91-040-23202465/2320

Management

- (Chairman)

Open IPO’s

View All

FAQs

The share price of Venmax Drugs & Pharmaceuticals Ltd on the BSE is - as on -